Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc ), a neonatal Fc receptor blocker, ...

Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ex-China rights to a potential first-in-class ...

Secukinumab does not show greater clinical efficacy than placebo in patients with moderate-to-severe Graves' orbitopathy, ...

("GenSci"), RTW Investments, LP ("RTW"), and Yarrow Bioscience, Inc. ("Yarrow") today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized ...

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves' disease A ...

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...

Argenx SE has discontinued the phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED ...

Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s ...

Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth.

The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the trials for futility following its review of data from a pre-specified interim analysis.

Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...

The CALM-CAH Phase 3 study is a randomized, placebo-controlled trial evaluating atumelnant in adults with classic CAH, designed to assess reductions in excess androgens, improvements in glucocorticoid ...